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Denise A. Yardley1*, Adam Brufsky2, Robert E. Coleman3, Pierfranco F. Conte4, Javier Cortes5, Stefan Glück6,
Jean-Mark A. Nabholtz7, Joyce O’Shaughnessy8, Robert M. Beck6, Amy Ko6, Markus F. Renschler6,
Debora Barton6 and Nadia Harbeck9Unfortunately, the original version of this article [1]
contained a few formatting errors which have been
corrected via an update. In the eighth paragraph of the
background there was an error. The original read as, “A
phase II study evaluating the combination of nab-
paclitaxel plus carboplatin as 199 first-line treatment for
mTNBC is currently under way [31].” But should have
read as “A phase II study evaluated the combination of
nab-paclitaxel plus carboplatin a first-line treatment for
mTNBC [31].”
Author details
1Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250
25th Avenue North, Suite 100, Nashville, TN 37203, USA. 2University of
Pittsburgh Medical Center, Pittsburgh, PA, USA. 3Weston Park Hospital,
Sheffield Cancer Research Center, Sheffield, England. 4Department of Surgery,
Oncology and Gastroenterology, University of Padova, Padova, and Istituto
Oncologico Veneto IRCCS, Padova, Italy. 5Vall d’Hebron Institute of Oncology
(VHIO), Barcelona, Spain. 6Celgene Corporation, Summit, NJ, USA. 7Centre de
Lutte Contre le Cancer d’Auvergne, Clermont Ferrand, France. 8Texas
Oncology-Baylor Charles A. Sammons Center; US Oncology, Dallas, TX, USA.
9Breast Center, University of Munich, Munich, Germany.* Correspondence: dyardley@tnonc.com
1Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250
25th Avenue North, Suite 100, Nashville, TN 37203, USA
© 2016 Yardley et al. Open Access This article
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeReference
1. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Phase
II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus
gemcitabine/carboplatin as first-line treatment of patients with metastatic
triple-negative breast cancer (the tnAcity study): study protocol for a
randomized controlled trial. Trials. 2015;16:575.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
